D. Tugay Et Al. , "Real-world patient-level cost-effectiveness analysis of omalizumab in patients with severe allergic asthma treated in four major medical centers in Turkey.," Journal of medical economics , vol.26, no.1, pp.720-730, 2023
Tugay, D. Et Al. 2023. Real-world patient-level cost-effectiveness analysis of omalizumab in patients with severe allergic asthma treated in four major medical centers in Turkey.. Journal of medical economics , vol.26, no.1 , 720-730.
Tugay, D., Top, M., Aydin, Ö., Bavbek, S., Damadoğlu, E., Öner Erkekol, F., ... Koca Kalkan, I.(2023). Real-world patient-level cost-effectiveness analysis of omalizumab in patients with severe allergic asthma treated in four major medical centers in Turkey.. Journal of medical economics , vol.26, no.1, 720-730.
Tugay, Deniz Et Al. "Real-world patient-level cost-effectiveness analysis of omalizumab in patients with severe allergic asthma treated in four major medical centers in Turkey.," Journal of medical economics , vol.26, no.1, 720-730, 2023
Tugay, Deniz Et Al. "Real-world patient-level cost-effectiveness analysis of omalizumab in patients with severe allergic asthma treated in four major medical centers in Turkey.." Journal of medical economics , vol.26, no.1, pp.720-730, 2023
Tugay, D. Et Al. (2023) . "Real-world patient-level cost-effectiveness analysis of omalizumab in patients with severe allergic asthma treated in four major medical centers in Turkey.." Journal of medical economics , vol.26, no.1, pp.720-730.
@article{article, author={Deniz Tugay Et Al. }, title={Real-world patient-level cost-effectiveness analysis of omalizumab in patients with severe allergic asthma treated in four major medical centers in Turkey.}, journal={Journal of medical economics}, year=2023, pages={720-730} }